Cytek BiosciencesCTKB
Recorded

Cytek Biosciences 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration30 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and thank you for standing by. My name is Lacey, and I will be your conference operator today. At this time, I would like to welcome everyone to the Cytek Biosciences Third Quarter 2026 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Mark Meehan, Head of Investor Relations.

Mark MeehanHead of Investor Relations

Please go ahead. Thank you, operator.

Mark MeehanHead of Investor Relations

Joining me today from Cytek are Wenbin Jiang, CEO, and Bill McCombe, CFO. Earlier today, Cytek Biosciences released financial results for the third quarter ended September 30, 2026. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors@cytekbio.com. A copy of the news release is also available on the investor relations section of Cytek's website at investors.cytekbio.com. Please note that we will be referencing a slide presentation during the call today that has been posted to the investor section of our corporate website. As a reminder, on slide two, we will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek's business plans, strategies, opportunities, and financial projections.

Mark MeehanHead of Investor Relations

These statements are based on the company's current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those anticipated in these statements. Additional information regarding these risks and uncertainties appears in our slide presentation in the section entitled Forward-Looking Statements, in the press release Cytek issued today, and in Cytek's filings with the SEC. This call will also include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles. Additional information regarding our use of non-GAAP financial measures, including reconciliations to the most directly comparable GAAP financial measures, may be found in our slide presentation and in today's press release.

Mark MeehanHead of Investor Relations

While the company believes these non-GAAP financial measures provide useful information for investors, the presentation of this information is not intended to be considered in isolation or as a substitute for the financial information presented in accordance with GAAP. This call will also provide a brief update about our active patent litigation. For more complete information about this case, as well as countersuits that we have instituted, please refer to our previous press release, as well as our SEC filings, including our Form 10-Q to be filed today. Except as required by law, Cytek disclaims any duty to update forward-looking statements, whether because of new information, future events, or changes in its expectations. This conference call contains time-sensitive information and is accurate only as of the live broadcast, November 4, 2026. With that, I will turn the call over to Wenbin.

Wenbin JiangCEO

Thanks, Mark. Welcome, everyone, and thank you for your interest in Cytek. On today's call, I will start with a discussion on our performance in the third quarter and review some business highlights before turning the call over to Bill for a detailed look at our financial results and our full-year outlook. Turning to slides three and four. We delivered another solid result in the third quarter with revenue of $53.2 million, an increase of 2% year-over-year. Our third quarter was highlighted by growth in the U.S., driven by continued strong demand for our high-end Full Spectrum Profiling instruments, led by Aurora Evo, the double-digit growth in our service business, and by our robust gross margin performance.

Wenbin JiangCEO

Growth in the third quarter was led by the U.S., where revenue grew 12% year-over-year to $30.4 million, continued strong momentum from the first half, driven by instrument sales to academic and government customers, and continued service growth. In EMEA, third-quarter revenue was $12.5 million, up 1% year-over-year, a positive sign after a challenging first half that reflected improving instrument sales to academic and government customers. Total APAC revenue, including China, was $8.3 million, up 5% sequentially versus Q2, while being down 25% compared to a strong Q3 last year. Turning to slide five. The third quarter was highlighted by success at the high end, where our technology leadership continues to shine. Customers are choosing Aurora Evo as it lets them run large panels and get consistent, reproducible data at higher throughput.

Wenbin JiangCEO

The automation configurations we introduced last quarter further increased the value to customers, with the API for automated plate handling systems fitting well into the high-volume workflows of our pharma and CRO customers. Combined Aurora and Aurora Evo placements grew 23% year-over-year, with Evo placements nearly doubling year-over-year, reflecting robust demand for our next-generation platform. As a result of strong placements, high-end Full Spectrum Profiling instrument revenue grew 11%. Across the broader business, we added a total of 140 instruments in the quarter, bringing our total install base to 4,073 units. Borealis, our newest platform, which we introduced last quarter, is receiving strong interest from customers in both the academic and biopharma markets, and we doubled the size of our early access program during Q3.

Wenbin JiangCEO

As a reminder, Borealis is a seven-laser Full Spectrum Profiling cytometer with 60-color performance already demonstrated, and a clear path to go higher as new dyes and panels are developed. It will also include integrated imaging capabilities when we get to full commercial launch. Paired with our new proprietary cFluor reagent, Borealis enables 60-color panels in a single tube while also supporting nanoparticle analysis and higher sampling rates. Early access program customers are excited about how these capabilities can enhance insight and accelerate discovery in their labs. We will continue to expand the early access program in the fourth quarter, with a broader commercial launch planned for fiscal year 2027. Turning to slide six. During the third quarter, we launched a new Cytek Cloud analysis tool, the industry's first end-to-end platform that integrates the entire flow cytometry workflow from panel design to data analysis into one system.

Wenbin JiangCEO

This will allow researchers to have a seamless experience from experiment planning through data analysis, reducing the need to move between systems or recreate workflows. Cloud analysis is available in the U.S. through Cytek Cloud Premium, a new subscription tier that adds cloud-based data analysis and online data storage. The launch is an important milestone towards our vision of Cytek Cloud as a comprehensive digital ecosystem that supports flow cytometry workflows from beginning to end. As of the end of the third quarter, the total Cytek Cloud user base is approaching 30,000, up more than 20% since the start of the year. Our recurring revenue base continued to grow in the third quarter. Combined service and reagent revenue was $19.1 million in Q3 2026 and represented 36% of Cytek's last 12-month revenue, up from 33% for the 12 months ended September 30, 2025.

Wenbin JiangCEO

We expect recurring revenue to represent an increasing percentage of total revenue over time. During the quarter, we also had important developments in our patent litigation case. As we announced on August 21st, a jury in the U.S. District Court for the District of Delaware found in our favor on three of the four asserted claims, finding both no infringement and invalidity for each of those three claims. On the fourth claim, the jury found no literal infringement, but did find infringement under the doctrine of equivalents. We do not believe that the applicable legal criteria for infringement under the doctrine of equivalents have been met. We filed post-trial motions asking the court to overturn the verdict on this and other grounds, and we intend to pursue all available legal remedies.

Wenbin JiangCEO

The jury's verdict does not require any change to our product offering or operations, and our ability to sell and ship products is not affected. Notably, the patent at issue is a U.S. patent and only applies to sales of instruments made in or imported into the United States. Finally, I wanted to share an update on the new business unit structure we introduced earlier this year. After careful review, we have decided to postpone the implementation of these business units until the start of 2027. We judged the near-term risk of moving to our new organization structure mid-year to be too significant. We remain confident that the new structure is the best way to support our long-term growth, but we recognize the critical need to deliver throughout the remainder of 2026.

Wenbin JiangCEO

We are continuing to focus resources and build out our team to grow our clinical and solution-focused instruments and reagents. Stepping back, we were pleased with the overall performance of our business. The third quarter was highlighted by continued success of our high-end Aurora Evo and Borealis analyzers by the double-digit growth in our service business, and as Bill will detail shortly. The strong execution from our operation team, which resulted in our best third quarter gross margin since 2023. With top line performance in line with our prior expectations, we are reiterating the midpoint of our full year 2026 revenue guidance. With that, I will now turn the call over to Bill for additional details on our Q3 financials and our full year outlook.

Bill McCombeCFO

Thanks, Wenbin. Turning to slide seven. Third quarter revenue came in at $53.2 million, an increase of 2% compared to Q3 2025. The highlight for the quarter was the strong customer demand for our high-end analyzers, with revenue growth of over 30% for the Aurora Evo, and Borealis category. This was the major factor driving U.S. total revenue growth of 12% and instrument growth of 9%. EMEA revenue returned to modest total revenue growth of 1% year-over-year, and instrument growth of 3% after two quarters of declines. APAC, including China, grew 5% sequentially compared to Q2, but was down 25% compared to a strong Q3 2025. We saw particular strength in revenue from academic and government customers, which was up 38% year-over-year to $24.5 million, with strength across all regions.

Bill McCombeCFO

In the U.S., the largest region for the academic and government end market, instrument revenue grew more than 60%. Biopharma distributor and CRO revenue declined approximately 17% year-over-year to $28.7 million against a strong Q3 last year. Product revenue, which is comprised of instruments and reagents, was $37.2 million, a decrease of 3% year-over-year, as strength in our high-end instruments was offset by declines in imaging and mid to low-end instruments. Service revenue grew 13% year-over-year, driven by growth in our installed base and continued active utilization of our systems. Turning to slide eight. Turning to gross margin, as Wenbin mentioned, we had an outstanding result with GAAP gross profit of $31.2 million in Q3, representing a gross margin of 59% compared to 53% in Q3 2025, an increase of nearly 600 basis points as we benefited from both higher product gross margin and higher service gross margin.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day